Ingalls & Snyder LLC Has $2.84 Million Stock Position in Genmab A/S (NASDAQ:GMAB)

Ingalls & Snyder LLC reduced its position in Genmab A/S (NASDAQ:GMAB) by 37.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 136,059 shares of the company’s stock after selling 82,424 shares during the period. Ingalls & Snyder LLC’s holdings in Genmab A/S were worth $2,840,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. boosted its position in shares of Genmab A/S by 94.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 26,104 shares of the company’s stock worth $636,000 after purchasing an additional 12,654 shares during the last quarter. HighTower Advisors LLC bought a new position in shares of Genmab A/S in the 3rd quarter worth $273,000. Verition Fund Management LLC bought a new position in shares of Genmab A/S in the 3rd quarter worth $709,000. FMR LLC boosted its position in shares of Genmab A/S by 13.5% in the 3rd quarter. FMR LLC now owns 278,194 shares of the company’s stock worth $6,782,000 after purchasing an additional 33,076 shares during the last quarter. Finally, Natixis Advisors LLC boosted its position in shares of Genmab A/S by 29.8% in the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company’s stock worth $5,036,000 after purchasing an additional 47,437 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $19.69 on Thursday. The firm has a market cap of $13.03 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 0.54 and a beta of 0.96. The stock’s 50-day moving average is $20.72 and its 200-day moving average is $23.24. Genmab A/S has a one year low of $18.64 and a one year high of $31.88.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. On average, equities analysts expect that Genmab A/S will post 1.25 EPS for the current year.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Thursday, January 23rd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and an average price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.